DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Center for Scientific Review; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: Center for Scientific Review Special Emphasis Panel; PAR13–309: Translational Research in Pediatric and Obstetric Pharmacology and Therapeutics.

Date: August 7, 2014.

Time: 1:00 p.m. to 4:00 p.m.

Agenda: To review and evaluate grant applications.

Place: National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892.

(Telephone Conference Call).

Contact Person: Nancy Shepard, SCD., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 6046-E, MSC 7892, Bethesda, MD 20892, 301–480–9901, sheardn@csr.nih.gov.

This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle.

Name of Committee: Center for Scientific Review Special Emphasis Panel; Channels and Receptors.

Date: August 8, 2014.

Time: 12:00 p.m. to 3:00 p.m.

Agenda: To review and evaluate grant applications.

Place: National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892.

(Telephone Conference Call).

Contact Person: Peter B Guthrie, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 4142, MSC 7850, Bethesda, MD 20892, (301) 435–1239, guthriep@csr.nih.gov.

This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle.


Carolyn A. Baum,
Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2014–18872 Filed 7–31–14; 8:45 am]
BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Substance Abuse and Mental Health Services Administration

Current List of HHS-Certified Laboratories and Instrumented Initial Testing Facilities Which Meet Minimum Standards To Engage in Urine Drug Testing for Federal Agencies

AGENCY: Substance Abuse and Mental Health Services Administration, HHS.

ACTION: Notice.

SUMMARY: The Department of Health and Human Services (HHS) notifies federal agencies of the laboratories and Instrumented Initial Testing Facilities (IITF) currently certified to meet the standards of the Mandatory Guidelines for Federal Workplace Drug Testing Programs (Mandatory Guidelines). The Mandatory Guidelines were first published in the Federal Register on April 11, 1988 (53 FR 11970), and subsequently revised in the Federal Register on June 9, 1994 (59 FR 29908); September 30, 1997 (62 FR 51118); April 13, 2004 (69 FR 64644); November 25, 2008 (73 FR 71858); December 10, 2008 (73 FR 75122); and on April 30, 2010 (75 FR 22809).

A notice listing all currently HHS-certified laboratories and IITFs is published in the Federal Register during the first week of each month. If any laboratory or IITF certification is suspended or revoked, the laboratory or IITF will be omitted from subsequent lists until such time as it is restored to full certification under the Mandatory Guidelines.

If any laboratory or IITF has withdrawn from the HHS National Laboratory Certification Program (NLCProgram) during the past month, it will be listed at the end and will be omitted from the monthly listing thereafter.

This notice is also available on the Internet at http://www.workplace.samhsa.gov.

FOR FURTHER INFORMATION CONTACT:
Giselle Hersh, Division of Workplace Programs, SAMHSA/CSAP, Room 7–1051, One Choke Cherry Road, Rockville, Maryland 20857; 240–276–2600 (voice), 240–276–2610 (fax).

SUPPLEMENTARY INFORMATION: The Mandatory Guidelines were initially reviewed and approved by the Special Emphasis Panel on Testing for Federal Agencies. The Panel meets on a quarterly basis to review and approve laboratories and IITFs for the Mandatory Guidelines. Laboratories and IITFs that are certified with full certification under the Mandatory Guidelines are listed in the Federal Register monthly thereafter.
developed in accordance with Executive Order 12564 and section 503 of Public Law 100–71. The “Mandatory Guidelines for Federal Workplace Drug Testing Programs,” as amended in the revisions listed above, requires strict standards that laboratories and IITFs must meet in order to conduct drug and specimen validity tests on urine specimens for federal agencies.

To become certified, an applicant laboratory or IITF must undergo three rounds of performance testing plus an on-site inspection. To maintain that certification, a laboratory or IITF must participate in a quarterly performance testing program plus undergo periodic, on-site inspections. Laboratories and IITFs in the applicant stage of certification are not to be considered as meeting the minimum requirements described in the HHS Mandatory Guidelines. A HHS-certified laboratory or IITF must have its letter of certification from HHS/SAMHSA (formerly: HHS/NIDA), which attests that it has met minimum standards. In accordance with the Mandatory Guidelines dated November 25, 2008 (73 FR 71858), the following HHS-certified laboratories and IITFs meet the minimum standards to conduct drug and specimen validity tests on urine specimens:

**HHS-Certified Instrumented Initial Testing Facilities**

<table>
<thead>
<tr>
<th>Laboratory Name</th>
<th>Address</th>
<th>Phone Numbers</th>
</tr>
</thead>
<tbody>
<tr>
<td>Baptist Medical Center-Toxicology Laboratory</td>
<td>11401 I–30, Little Rock, AR 72209–3705</td>
<td>501–202–2783</td>
</tr>
<tr>
<td>(Formerly: Forensic Toxicology Laboratory Baptist Medical Center)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Clinical Reference Lab</td>
<td>8433 Quivira Road, Lenexa, KS 66215–2902</td>
<td>800–445–6917</td>
</tr>
<tr>
<td>DrugScan, Inc.,</td>
<td>200 Precision Road, Suite 200, Horsham, PA 19044</td>
<td>800–235–4890</td>
</tr>
<tr>
<td>ElSohly Laboratories, Inc.,</td>
<td>5 Industrial Park Drive, Oxford, MS 38655</td>
<td>662–236–2609</td>
</tr>
<tr>
<td>Fortes Laboratories, Inc.,</td>
<td>25749 SW Canyon Creek Road, Suite 600, Wilsonville, OR 97070</td>
<td>503–486–1023</td>
</tr>
<tr>
<td>Gamma-Dynacare Medical Laboratories, A Division of the</td>
<td>245 Pall Mall Street, London, ONT, Canada N6A 1P4</td>
<td>519–679–1630</td>
</tr>
<tr>
<td>Gamma-Dynacare Laboratory Partnership</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Laboratory of America</td>
<td>7207 N. Gessner Road, Houston, TX 77040</td>
<td>713–856–8288/800–200–2387</td>
</tr>
<tr>
<td>(Formerly: Roche Biomedical Laboratories, Inc.)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Laboratory Corporation of America Holdings, 1904 Alexander Drive,</td>
<td>Research Triangle Park, NC 27709</td>
<td>919–572–6900/800–833–3984</td>
</tr>
<tr>
<td>(Formerly: LabCorp Occupational Testing Services, Inc.;</td>
<td>Compuchem Laboratories, Inc.; Compuchem Laboratories Laboratories, Inc., A Subsidiary of</td>
<td></td>
</tr>
<tr>
<td>(Formerly: Roche Biomedical Laboratory; Roche Compuchem Laboratories Laboratories, Inc., A Member of the Roche Group)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Laboratory Corporation of America Holdings,</td>
<td>1120 Main Street, Southaven, MS 38671</td>
<td>662–827–8042/800–233–6339</td>
</tr>
<tr>
<td>(Formerly: LabCorp Occupational Testing Services, Inc.; MedExpress/National Laboratory Center)</td>
<td>662–827–8042/800–233–6339</td>
<td></td>
</tr>
<tr>
<td>MedOne, Inc. d/b/a Quest Diagnostics,</td>
<td>10101 Renner Blvd., Lenexa, KS 66219</td>
<td>913–888–3927/800–873–8845</td>
</tr>
<tr>
<td>(Formerly: Quest Diagnostics Incorporated; LabOne, Inc.; Center for Laboratory Services, a Division of LabOne, Inc.)</td>
<td>662–827–8042/800–873–8845</td>
<td></td>
</tr>
<tr>
<td>Minneapolis Veterans Affairs Medical Center, Forensic Toxicology Laboratory</td>
<td>1 Veterans Drive, Minneapolis, MN 55417, 612–725–2088</td>
<td></td>
</tr>
<tr>
<td>National Toxicology Laboratories, Inc.,</td>
<td>1100 California Ave., Bakersfield, CA 93304</td>
<td>661–322–4250/800–350–3515</td>
</tr>
<tr>
<td>Ope Source Toxicology Laboratory, Inc.,</td>
<td>1213 Genoa-Red Bluff, Pasadena, TX 77504</td>
<td>888–747–3774</td>
</tr>
<tr>
<td>(Formerly: University of Texas Medical Branch, Clinical Chemistry Division; UTMB Pathology-Toxicology Laboratory)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pacific Toxicology Laboratories, 9348 DeSoto Ave., Chatsworth, CA 91311</td>
<td>800–328–6942, (Formerly: Centinela Hospital Airport Toxicology Laboratory)</td>
<td></td>
</tr>
<tr>
<td>Pathology Associates Medical Laboratories, 110 West Cliff Dr., Spokane, WA 99204</td>
<td>509–755–8991/800–541–7891X7</td>
<td></td>
</tr>
<tr>
<td>Phamatech, Inc., 10151 Barnes Canyon Road, San Diego, CA 92121</td>
<td>858–643–5555</td>
<td></td>
</tr>
<tr>
<td>Quest Diagnostics Incorporated, 1777 Montreal Circle, Tucker, GA 30084</td>
<td>800–729–6432, (Formerly: SmithKline Beecham Clinical Laboratories; SmithKline Bio-Science Laboratories)</td>
<td></td>
</tr>
<tr>
<td>Quest Diagnostics Incorporated, 8401 Fallbrook Ave., West Hills, CA 91304, 818–737–6370, (Formerly: SmithKline Beecham Clinical Laboratories)</td>
<td>818–737–6370, (Formerly: SmithKline Beecham Clinical Laboratories)</td>
<td></td>
</tr>
<tr>
<td>Redwood Toxicology Laboratory, 3700650 Westwind Blvd., Santa Rosa, CA 95403, 800–255–2159</td>
<td>800–255–2159</td>
<td></td>
</tr>
<tr>
<td>STERLING Reference Laboratories, 2617 East L Street, Tacoma, Washington 98421, 800–442–0438</td>
<td>800–442–0438</td>
<td></td>
</tr>
<tr>
<td>U.S. Army Forensic Toxicology Drug Testing Laboratory, 2409 Wilson St., Fort George G. Meade, MD 20755–5235, 301–677–7085</td>
<td>2409 Wilson St., Fort George G. Meade, MD 20755–5235, 301–677–7085</td>
<td></td>
</tr>
</tbody>
</table>

* The Standards Council of Canada (SCC) voted to end its Laboratory Accreditation Program for Substance Abuse (LAPSA) effective May 12, 1998. Laboratories certified through that program were accredited to conduct forensic urine drug testing as required by U.S. Department of Transportation (DOT) regulations. As of that date, the certification of those accredited Canadian laboratories will continue under DOT authority. The responsibility for conducting quarterly performance testing plus periodic on-site inspections of those LAPSA-accredited laboratories was transferred to the U.S. HHS, with the HHS’ NLCP contractor continuing to have an active role in the performance testing and laboratory inspection processes. Other Canadian laboratories wishing to be considered for the NLCP may apply directly to the NLCP contractor just as U.S. laboratories do. Upon finding a Canadian laboratory to be qualified, HHS will recommend that
DOT certify the laboratory (Federal Register, July 16, 1996) as meeting the minimum standards of the Mandatory Guidelines published in the Federal Register on April 30, 2010 (75 FR 22809). After receiving DOT certification, the laboratory will be included in the monthly list of HHS-certified laboratories and participate in the NLCP certification maintenance program.

Janine Denis Cook,
Chemist, Division of Workplace Programs, Center for Substance Abuse Prevention, SAMHSA.


DEPARTMENT OF HEALTH AND HUMAN SERVICES
Substance Abuse and Mental Health Services Administration

Notice of Meeting

Pursuant to Public Law 92–463, notice is hereby given of the combined meeting on August 27, 2014, of the Substance Abuse and Mental Health Services Administration’s (SAMHSA) four National Advisory Councils (the SAMHSA National Advisory Council (NAC), the Center for Mental Health Services NAC, the Center for Substance Abuse Prevention NAC, the Center for Substance Abuse Treatment NAC), and the two SAMHSA Advisory Committees (Advisory Committee for Women’s Services, and the Tribal Technical Advisory Committee).

The Councils were established to advise the Secretary, Department of Health and Human Services (HHS), the Administrator, SAMHSA, and Center Directors, concerning matters relating to the activities carried out by and through the Centers and the policies respecting such activities.

Under Section 501 of the Public Health Service Act, the Advisory Committee for Women’s Services (ACWS) is statutorily mandated to advise the SAMHSA Administrator and the Associate Administrator for Women’s Services on appropriate activities to be undertaken by SAMHSA and its Centers with respect to women’s substance abuse and mental health services.

Pursuant to Presidential Executive Order No. 13175, November 6, 2000, and the Presidential Memorandum of September 23, 2004, SAMHSA established the Tribal Technical Advisory Committee (TTAC) for working with Federally-recognized Tribes to enhance the government-to-government relationship, honor Federal trust responsibilities and obligations to Tribes and American Indian and Alaska Natives. The SAMHSA TTAC serves as an advisory body to SAMHSA.

The August 27 combined meeting will include a report from the SAMHSA Administrator, an update and discussion regarding Military members returning home and their families.

The meeting is open to the public and will be held online via Chorus Call and teleconference. Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee. Written submissions should be forwarded to the contact person on or before August 18, 2014. Oral presentations from the public will be scheduled at the conclusion of the meeting. Individuals interested in making oral presentations are encouraged to notify the contact on or before August 18, 2014. Five minutes will be allotted for each presentation.

Substantive program information may be obtained after the meeting by accessing the SAMHSA Committee Web site, http://nac.samhsa.gov/, or by contacting Ms. Wood.

Committee Names: Substance Abuse and Mental Health Services Administration National Advisory Council; Center for Mental Health Services National Advisory Council; Center for Substance Abuse Prevention National Advisory Council; Center for Substance Abuse Treatment National Advisory Council; SAMHSA’s Advisory Committee for Women’s Services; SAMHSA Tribal Technical Advisory Committee.

Date/Time/Type: Wednesday, August 27, 2014, 1:00 p.m.–4:00 p.m. EDT (OPEN).

Place: Chorus call Web cast: http://services.choruscall.com/links/samhsa140827.html; Call-in Number (866) 652–5200; Passcode: SAMHSA.

Contact: Geretta Wood, Committee Management Officer and Designated Federal Official, SAMHSA National Advisory Council, SAMHSA’s Advisory Committee for Women’s Services, 1 Choke Cherry Road, Rockville, Maryland 20857, Telephone: (240) 276–2326, Fax: (240) 276–2253 and Email: geretta.wood@samhsa.hhs.gov.

Cathy J. Friedman,
Public Health Analyst, SAMHSA.


DEPARTMENT OF HEALTH AND HUMAN SERVICES
Substance Abuse and Mental Health Services Administration

National Advisory Committee Notice of Meeting

Pursuant to Public Law 92–463, notice is hereby given of the meeting on of the Substance Abuse and Mental Health Services Administration’s (SAMHSA) National Advisory Committee on August 28, 2014.

The meeting will include an update from the SAMHSA Administrator and discussions regarding Healthcare and Parity Implementation.

The meeting is open to the public and will be held online via Microsoft Office 2007 Live Meeting. Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee. Written submissions should be forwarded to the contact person on or before August 18, 2014. Oral presentations from the public will be scheduled at the conclusion of the meeting. Individuals interested in making oral presentations are encouraged to notify the contact on or before August 18, 2014. Five minutes will be allotted for each presentation.

Substantive program information may be obtained after the meeting by accessing the SAMHSA Committee Web site, http://nac.samhsa.gov/, or by contacting Geretta P. Wood.

Committee Name: Substance Abuse and Mental Health Services Administration National Advisory Committee (NAC)

Date/Time/Type: August 28, 2014 from 1:00 p.m. to 4:00 p.m. EDT (OPEN)

Place: Live meeting webcast: https://www.mymeetings.com/n/join.php?i=PW7187982&p=AMHSA%20NAC&c=

Conference number: PW7187982.

Audience passcode: SAMHSA NAC.

Dial in number: 888–968–4347.

Contact: Geretta Wood, Committee Management Officer and Designated Federal Official, SAMHSA National Advisory Council, SAMHSA’s Advisory Committee for Women’s Services, 1 Choke Cherry Road, Rockville, Maryland 20857, Telephone: (240) 276–2326, Fax: (240) 276–2253 and Email: geretta.wood@samhsa.hhs.gov.

Cathy J. Friedman,
Public Health Analyst, SAMHSA.
